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Since emergence of the pandemic (H1N1) 2009 virus 
in April 2009, three infl uenza A viruses—seasonal (H3N2), 
seasonal (H1N1), and pandemic (H1N1) 2009—have cir-
culated in humans. Genetic reassortment between these 
viruses could result in enhanced pathogenicity. We com-
pared 4 reassortant viruses with favorable in vitro replica-
tion properties with the wild-type pandemic (H1N1) 2009 
virus with respect to replication kinetics in vitro and patho-
genicity and transmission in ferrets. Pandemic (H1N1) 2009 
viruses containing basic polymerase 2 alone or in combina-
tion with acidic polymerase of seasonal (H1N1) virus were 
attenuated in ferrets. In contrast, pandemic (H1N1) 2009 
with neuraminidase of seasonal (H3N2) virus resulted in 
increased virus replication and more severe pulmonary le-
sions. The data show that pandemic (H1N1) 2009 virus has 
the potential to reassort with seasonal infl uenza viruses, 
which may result in increased pathogenicity while it main-
tains the capacity of transmission through aerosols or respi-
ratory droplets.
The infl uenza virus A (H1N1) that caused the fi rst infl u-enza pandemic of the 21st century, pandemic (H1N1) 
2009, continues to be detected worldwide (1,2). The pan-
demic overall has been relatively mild; disease has ranged 
from subclinical infections to sporadic cases of severe 
pneumonia and acute respiratory distress syndrome (3–8). 
The virus responsible is a unique reassortant virus contain-
ing neuraminidase (NA) and matrix genes from the Eur-
asian swine infl uenza virus lineage, and the other 6 gene 
segments are derived from the North American triple reas-
sortant swine infl uenza virus lineage (9). From the pandem-
ic’s start, there have been concerns the virus may mutate or 
reassort with contemporary infl uenza viruses and give rise 
to more pathogenic viruses.
Cocirculation of multiple strains of infl uenza virus A 
in humans provides an opportunity for viral genetic reas-
sortment (mixing of genes from >2 viruses) (10). Genetic 
reassortment of pandemic (H1N1) 2009 virus with seasonal 
infl uenza A (H3N2) or seasonal infl uenza A (H1N1) viruses 
might thus represent a route to enhanced pathogenicity. No 
reassortment events between pandemic (H1N1) 2009 and 
seasonal viruses have been reported in humans. However, a 
triple-reassortant swine infl uenza virus A (H1N1), distinct 
from pandemic (H1N1) 2009 virus and containing the he-
magglutinin (HA) and NA genes of seasonal infl uenza vi-
rus A (H1N1), was described recently (11). Dual infections 
by seasonal infl uenza A (H1N1) and seasonal infl uenza A 
(H3N2) viruses have been reported (12), as well as mixed 
infections of pandemic (H1N1) 2009 and seasonal infl u-
enza A (H3N2) viruses (13,14), highlighting the potential 
for reassortment of currently circulating infl uenza viruses. 
Subtype H1N2 reassortant infl uenza viruses that contain 
the HA of seasonal infl uenza A (H1N1) and the NA of sea-
sonal infl uenza A (H3N2) viruses have been isolated from 
humans during previous infl uenza seasons, confi rming that 
such HA/NA combinations can emerge in humans (15,16). 
To investigate the potential for reassortment between 
seasonal infl uenza A and pandemic (H1N1) 2009 viruses, 
we used an in vitro selection method using reverse genet-
ics and serial passaging under limited dilution conditions. 
Pathogenicity and transmission of these viruses were tested 
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by using a ferret model. We report here the identifi cation of 
4 reassortants with different gene constellations. 
Materials and Methods
Cells and Viruses
MDCK cells were cultured in Eagle minimum es-
sential medium as described (17). Infl uenza virus A/
Netherlands/602/2009 was isolated from the fi rst patient 
with pandemic (H1N1) 2009 virus infection in the Neth-
erlands (18). Infl uenza virus A/Netherlands/213/2003 
(seasonal infl uenza A [H3N2]) and infl uenza virus A/
Netherlands/26/2007 (seasonal infl uenza A [H1N1]) were 
isolated from patients during epidemics in the Netherlands. 
After these viruses were passaged in MDCK cells 2×, all 
8 gene segments were amplifi ed by reverse transcription–
PCR, cloned in a modifi ed version of the bidirectional re-
verse genetics plasmid pHW2000 (19,20), and subsequent-
ly used to generate recombinant virus by reverse genetics 
as described elsewhere (19).
Generation of the Reassortant Viruses
Mixtures of reassortant viruses were generated in 293T 
cells by using reverse genetics, by co-transfecting 8 plas-
mids that encode the pandemic (H1N1) 2009 virus genome 
together with 7 plasmids encoding the seasonal infl uenza A 
(H3N2) or seasonal infl uenza A (H1N1) virus genome. We 
omitted HA of the seasonal viruses to ensure that only reas-
sortants containing the pandemic (H1N1) 2009 virus HA 
could arise, against which a large proportion of the human 
population is still immunologically naïve (21). The 293T-
cell supernatants were passaged in quadruplicate under lim-
iting dilution conditions by using 10-fold serial dilutions in 
MDCK cells 3× to enable selective outgrowth of viruses 
with high in vitro replication rates. After 3 passages, the 
genome composition of these viruses was determined by 
sequencing with conserved primers targeting noncoding 
regions of each gene segment. Reverse genetics was also 
used to produce specifi c reassortant viruses (pandemic 
[H1N1] 2009–seasonal infl uenza A [H1N1] basic poly-
merase [PB] 2, pandemic [H1N1] 2009–seasonal infl uenza 
A [H1N1] PB2 acidic polymerase [PA], pandemic [H1N1] 
2009–seasonal infl uenza A [H3N2] NA, and pandemic 
[H1N1] 2009–seasonal infl uenza A [H3N2] NAPB1) by 
transfection of 293T cells and subsequent virus propaga-
tion in MDCK cells. 
In Vitro Characterization of Viruses
Multicycle replication curves were generated by in-
jecting MDCK cells at a multiplicity of infection of 0.01 
50% tissue culture infective dose (TCID50) per cell in 2-fold 
(17). Virus titers from samples of inoculated MDCK cells, 
as well as nasal and throat swabs or homogenized tissue 
samples from inoculated ferrets, were determined by end-
point titration in MDCK cells, as described (22).
Ferret Experiments
All animal studies were approved by an independent 
animal ethics committee. Experiments were performed 
under animal BioSafety Level 3+ conditions. The ferret 
model to test pathogenicity and transmission of pandemic 
(H1N1) 2009 virus was described previously (17,18). To 
study pathogenicity, 5 groups of 6 infl uenza virus–serone-
gative female ferrets (Mustella putorius furo) were inocu-
lated intranasally with 106 TCID50 of wild-type pandemic 
(H1N1) 2009 virus, or the reassortant viruses pandemic 
(H1N1) 2009–seasonal infl uenza A (H1N1) PB2, pandem-
ic (H1N1) 2009–seasonal infl uenza A (H1N1) PB2PA, 
pandemic (H1N1) 2009–seasonal infl uenza A (H3N2) NA, 
and pandemic (H1N1) 2009–seasonal infl uenza A (H3N2) 
NAPB1, divided between both nostrils (2 × 250 μL). In 
the transmission experiment, 4 female ferrets for wild-
type pandemic (H1N1) 2009 virus and 2 ferrets for each 
reassortant virus were individually housed in transmission 
cages and inoculated intranasally with 106 TCID50 of virus 
divided between both nostrils (2 × 250 μL). Animal daily 
weights were used as an indicator of disease.   
Immunohistochemistry and Histopathology
Immunohistochemical testing and pathologic exami-
nation were performed by using lungs of inoculated fer-
rets. For each virus, 3 ferrets were euthanized at 3 and 7 
days postinoculation (dpi) by exsanguination. Necropsies 
and tissue sampling were performed according to standard 
protocol. After fi xation in 10% neutral-buffered formalin 
and embedding in paraffi n, samples were sectioned at 4 μm 
and stained with an immunohistochemical method by using 
a mouse monoclonal antibody against the nucleoprotein of 
infl uenza virus A (23). Infl uenza virus antigen expression 
in lung sections was scored for bronchial surface epithe-
lium, bronchial submucosal gland epithelium, bronchiolar 
epithelium, alveolar type I pneumocytes, and alveolar type 
II pneumocytes. Scoring was categorized as 0, no positive 
cells; 1, few positive cells; 2, moderate number of positive 
cells; and 3, many positive cells. Serial lung sections were 
stained with hematoxylin and eosin for detection and de-
scription of pathologic changes. Samples were scored for 
infl uenza virus–associated infl ammation in bronchi (bron-
chitis), bronchial submucosal glands (bronchoadenitis), 
bronchioles (bronchiolitis), and alveoli (alveolitis). Scoring 
of severity of infl ammation was 0, no infl ammation; 1, mild 
infl ammation; 2, moderate infl ammation; and 3, marked in-
fl ammation. Researchers who examined the sections had 
no knowledge of the identity of the ferrets.
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Results
In Vitro Selection of Reassortants
The proportion of gene segments 1–8 (except HA) ana-
lyzed was ≈60%, 60%, 65%, 90%, 95%, 100%, and 100%, 
respectively. Minor virus variants were not detected. No 
point mutations were observed in the proportions of the 
genome analyzed. Upon pandemic (H1N1) 2009–seasonal 
infl uenza A (H1N1) transfection and passaging, 3 reassor-
tants contained the PB2 gene of seasonal infl uenza virus 
A (H1N1), 2 of which had also incorporated the seasonal 
(H1N1) PA gene. All 4 pandemic (H1N1) 2009–seasonal 
infl uenza A (H3N2) virus reassortants had the NA gene of 
seasonal infl uenza A (H3N2), and 3 of 4 reassortants also 
incorporated the seasonal infl uenza A (H3N2) PB1 gene 
(Table 1).
In Vitro Characterization of Pandemic (H1N1) 2009–
Seasonal Infl uenza A (H1N1) and Pandemic (H1N1) 
2009–Seasonal Infl uenza A (H3N2) Reassortants
The replication kinetics of pandemic (H1N1) 2009–
seasonal infl uenza A (H1N1) PB2 and pandemic (H1N1) 
2009–seasonal infl uenza A (H1N1) PB2PA were similar to 
those of wild-type pandemic (H1N1) 2009 virus, and the 
pandemic (H1N1) 2009–seasonal infl uenza A (H3N2) NA 
and pandemic (H1N1) 2009–seasonal infl uenza A (H3N2) 
NAPB1 reassortant viruses displayed slightly higher virus 
titers at 24 and/or 48 h after inoculation, with a maximum 
difference in virus titer of 1.0 log10 TCID50 (Figure 1). The 
fact that each reassortant virus replicated at least at the 
same rate as the wild-type pandemic (H1N1) 2009 virus 
agrees with results from the in vitro selection experiment 
described above.
Pathogenicity of the Reassortant Viruses in Ferrets
The mean maximum weight loss was 7% for animals 
inoculated with the pandemic (H1N1) 2009 virus. Animals 
inoculated with pandemic (H1N1) 2009–seasonal infl u-
enza A (H1N1) PB2PA, pandemic (H1N1) 2009–seasonal 
infl uenza A (H1N1) PB2, pandemic (H1N1) 2009–sea-
sonal infl uenza A (H3N2) NAPB1 and pandemic (H1N1) 
2009–seasonal infl uenza A (H3N2) NA had a maximum 
weight loss of 4%, 2%, 2%, and 6%, respectively (data not 
shown).
Nose and throat swabs were collected daily, and virus 
titers were determined. Infectious virus shedding continued 
until 6–7 days dpi from noses (Figure 2, panels A and C) 
and throats (Figure 2, panels B and D) of most inoculated 
animals. Total virus shedding from the nose, as calculated 
from the area under the curve for ferrets in the experiment 
for 7 days (n = 3), was signifi cantly lower in animals inocu-
lated with the pandemic (H1N1) 2009–seasonal infl uenza 
A (H1N1) PB2 reassortant virus (p = 0.003 by t test) and 
signifi cantly higher in the animals inoculated with the pan-
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Table 1. Predominant virus genome composition upon in vitro selection of mixtures of pandemic (H1N1) 2009–seasonal (H1N1) and 
pandemic (H1N1)–seasonal (H3N2) influenza virus reassortants* 
Replicates PB2 PB1 PA HA NP NA M NS
Pandemic (H1N1) 2009–seasonal (H1N1) 1 sH1 pH1 sH1 pH1 pH1 pH1 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H1N1) 2 sH1 pH1 sH1 pH1 pH1 pH1 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H1N1) 3 sH1 pH1 pH1 pH1 pH1 pH1 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H1N1) 4 pH1 pH1 pH1 pH1 pH1 pH1 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H3N2) 1 pH1 sH3 pH1 pH1 pH1 sH3 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H3N2) 2 pH1 pH1 pH1 pH1 pH1 sH3 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H3N2) 3 pH1 sH3 pH1 pH1 pH1 sH3 pH1 pH1 
Pandemic (H1N1) 2009–seasonal (H3N2) 4 pH1 sH3 pH1 pH1 pH1 sH3 pH1 pH1 
*PB, basic polymerase; PA, acidic polymerase; HA, hemagglutinin; NP, nucleoprotein; NA, neuraminidase; M, matrix; NS, nonstructural; sH1, seasonal 
influenza A virus (H1N1); pH1, pandemic (H1N1) 2009 virus; sH3, seasonal influenza A (H3N2) virus. 
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Figure 1. Replication of wild-type and reassortant pandemic 
(H1N1) 2009 viruses in MDCK cells. MDCK cells were injected in 
duplicate with 0.01 50% tissue culture infective dose (TCID50) per 
cell of each virus: black, wild-type pandemic (H1N1) 2009; red, 
reassortant pandemic (H1N1) 2009–seasonal infl uenza (H1N1) 
basic polymerase (PB) 2 acidic polymerase; blue, reassortant 
pandemic (H1N1) 2009–seasonal infl uenza (H1N1) PB2; green, 
reassortant pandemic (H1N1) 2009–seasonal infl uenza (H3N2) 
PB1 neuraminidase (NA); orange, reassortant pandemic (H1N1)–
seasonal infl uenza (H3N2) NA. Supernatant samples were 
harvested 6, 12, 24 and 48 h after injection. Supernatant samples 
were titrated in MDCK cells. Geometric mean titers and standard 
deviation were calculated from 2 independent experiments.
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demic (H1N1) 2009–seasonal infl uenza virus A (H3N2) 
NA (p = 0.023 by t test), than in animals inoculated with 
wild-type pandemic (H1N1) 2009 virus. Total virus shed-
ding from the throat, as calculated from the area under the 
curve for ferrets in the experiment for 7 days, was not sig-
nifi cantly different between the groups of ferrets.
At 3 and 7 dpi, 3 ferrets from each group were eu-
thanized, and samples from nasal turbinates, trachea, and 
lungs were collected for virologic examination. At 7 dpi, 
virus was undetectable or detected at only very low lev-
els in these samples from all groups of ferrets. At 3 dpi, 
no virus or relatively low virus titers were detected in the 
lungs and trachea respectively, of ferrets inoculated with 
pandemic (H1N1) 2009–seasonal infl uenza A (H1N1) 
reassortant viruses (Figure 3, panels A and B), and titers 
in the nasal turbinates were similar to those for wild-type 
pandemic (H1N1) 2009 virus (Figure 3, panel C). These 
data indicate that both pandemic (H1N1) 2009–seasonal 
infl uenza A (H1N1) viruses were attenuated with respect to 
replication in the lower respiratory tract of ferrets.
At 3 dpi, virus was detected in the lungs, trachea, and 
nasal turbinates of ferrets inoculated with pandemic (H1N1) 
2009–seasonal infl uenza A (H3N2) NAPB1 and pandemic 
(H1N1) 2009–seasonal infl uenza A (H3N2) NA viruses at 
approximately the same levels as upon inoculation with 
wild-type pandemic (H1N1) 2009 virus (Figure 3, panels 
D–F). Virus titers detected in the lungs and trachea of ani-
mals inoculated with pandemic (H1N1)–seasonal infl uenza 
virus A (H3N2) NA at 3 dpi were 1.0 log10 TCID50 higher 
than those in animals inoculated with wild-type pandemic 
(H1N1) 2009 virus (not statistically signifi cant). These data 
indicate that both pandemic (H1N1) 2009–seasonal infl u-
enza A (H3N2) viruses tested were not attenuated in fer-
rets. If anything, shedding of pandemic (H1N1)–seasonal 
infl uenza A (H3N2) NA virus from the nose (Figure 2, 
panel C), lungs (Figure 3, panel D), and trachea (Figure 3, 
panel E) was higher than shedding of wild-type pandemic 
(H1N1) 2009 virus. 
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Figure 2. Virus shedding from the nose and throat of ferrets inoculated with wild-type and reassortant pandemic (H1N1) 2009 viruses. 
Virus shedding from nose (A, C) and throat (B, D) is shown for pandemic (H1N1) 2009–seasonal infl uenza (H1N1) (A, B) and pandemic 
(H1N1) 2009–seasonal infl uenza (H3N2) (C, D) reassortant viruses. Black, wild-type pandemic (H1N1) 2009; red, pandemic (H1N1) 
2009–seasonal infl uenza (H1N1) basic polymerase (PB) 2 acidic polymerase; blue, pandemic (H1N1) 2009–seasonal infl uenza (H1N1) 
PB2; green, pandemic (H1N1) 2009–seasonal infl uenza (H3N2) PB1 neuraminidase (NA); orange, pandemic (H1N1)–seasonal infl uenza 
(H3N2) NA. Geometric mean titers are shown; error bars indicate SD. The lower limit of detection is 0.5 log10 50% tissue culture infective 
dose/mL (TCID50/mL). After day 3, only 3 animals remained in each group.
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Pathologic Changes in the Respiratory Tract of 
Ferrets Inoculated with Pandemic (H1N1) 2009 
and Reassortant Viruses
At 7 dpi, virus antigen expression was undetectable in 
lung tissue of any of the euthanized ferrets, and lesions were 
absent or resolving. At 3 dpi, neither viral antigen expres-
sion nor lesions were detected in lungs of ferrets inoculated 
with pandemic (H1N1) 2009–seasonal infl uenza A (H1N1) 
PB2. Only 1 of 3 ferrets inoculated with pandemic (H1N1) 
2009 had scant virus antigen expression and mild associ-
ated lesions in bronchial submucosal glands and bronchi-
oles at 3 dpi (Table 2, Figure 4). In contrast, all 3 ferrets 
inoculated with pandemic (H1N1) 2009–seasonal infl uenza 
A (H3N2) NA had moderate to abundant virus antigen ex-
pression in bronchial submucosal glands, bronchioles, or 
both, associated with moderate to marked infl ammation 
(Table 2, Figure 4). Virus antigen expression and associat-
ed lesions in the lungs of ferrets inoculated with pandemic 
(H1N1) 2009–seasonal infl uenza A (H3N2) PB1NA were 
intermediate between those of wild-type pandemic (H1N1) 
2009 and pandemic (H1N1)–seasonal infl uenza A (H3N2) 
NA (Table 2).
Cell types in which virus antigen expression was de-
tected were ciliated epithelial cells of bronchi, epithelial 
cells of bronchial submucosal glands, ciliated and noncili-
ated cells of bronchioles, and both squamous and cuboidal 
epithelial cells (interpreted as type I and type II pneumo-
cytes, respectively) of alveoli (Figure 4). Virus antigen ex-
pression was also seen in desquamated epithelial cells and 
cell debris in lumina of above tissues.
Lesions associated with virus antigen expression can 
be categorized as acute, focal or multifocal, necrotizing 
bronchitis, bronchoadenitis, bronchiolitis, and alveolitis. 
These lesions were characterized by degeneration and ne-
crosis of epithelial cells, infi ltration of the affected tissues 
and their lumina by many neutrophils and few eosinophils, 
and exudation of edema fl uid and fi brin into tissue lumina.
Transmission of Reassortant Viruses in Ferrets
Transmission of pandemic (H1N1) 2009 and reas-
sortant infl uenza viruses through aerosol or respiratory 
droplets was tested in the ferret model. Ferrets in groups of 
4 for pandemic (H1N1) 2009 virus and 2 for the reassortant 
viruses were inoculated intranasally with 106 TCID50 of 
virus. At 1 dpi, an uninfected ferret was placed in a cage 
adjacent to each inoculated ferret. All viruses were trans-
mitted from the inoculated to the uninfected ferrets in 4/4 
ferrets for pandemic (H1N1) 2009 virus and 2/2 ferrets for 
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Figure 3. Virus detection in respiratory tissues of ferrets inoculated with wild-type and reassortant pandemic (H1N1) 2009 viruses. Virus 
detection in lungs (A, D), trachea (B, E), and nasal turbinates (C, F) is shown for pandemic (H1N1) 2009–seasonal infl uenza (H1N1) 
(A–C) and pandemic (H1N1) 2009–seasonal infl uenza (H3N2) (D–F) reassortant viruses. Black, wild-type pandemic (H1N1) 2009; red, 
pandemic (H1N1) 2009–seasonal infl uenza (H1N1) basic polymerase (PB) 2 acidic polymerase; blue, pandemic (H1N1) 2009–seasonal 
infl uenza (H1N1) PB2; green, pandemic (H1N1) 2009–seasonal infl uenza (H3N2) PB1 neuraminidase (NA); orange, pandemic (H1N1)–
seasonal infl uenza (H3N2) NA. Three ferrets of each group were euthanized at 3 and 7 days postinoculation. Geometric mean titers are 
shown; error bars indicate SD. The lower limit of detection is 0.5 log10 50% tissue culture infective dose/mL (TCID50/mL).
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each of the reassortant viruses. The fi rst day of virus detec-
tion in the previously uninfected animals was 2 days post 
exposure, similar for all viruses tested.
Discussion
We used an in vitro selection method to identify reas-
sortant viruses between pandemic (H1N1) 2009 virus and 
seasonal infl uenza A (H1N1) and infl uenza A (H3N2) vi-
ruses of interest for testing in a ferret model. Studying the 
effects of reassortment on changes in infl uenza virus phe-
notype is cumbersome because the number of reassortants 
that can be generated between 2 viruses is high; 28 = 256 
different viruses. After 3 passages, a limited number of spe-
cifi c virus populations were selected in vitro. Minor virus 
variants representing <20% of the virus population would 
remain undetected in our approach of PCR amplifi cation 
and direct determination of the consensus sequence of the 
amplicons. However, upon repeating the procedure 4 times 
for both reassortment combinations, the seasonal infl uenza 
virus genes that were selected in the pandemic (H1N1) 
2009 virus backbone were more or less consistent, with 
NA of seasonal infl uenza virus A (H3N2) being selected in 
4/4 attempts, PB1 of seasonal infl uenza A (H3N2) and PB2 
of seasonal infl uenza virus A (H1N1) in 3/4 attempts, and 
PA of seasonal infl uenza virus A (H1N1) in 2/4 attempts. 
Replication in MDCK cells may not be the best selection 
criterion for the identifi cation of reassortants of interest to 
human health. Nevertheless, we chose this in vitro selection 
method because previous work has shown that pandemic 
(H1N1) 2009 outcompetes seasonal infl uenza A (H1N1) 
and seasonal infl uenza A (H3N2) viruses rapidly, reducing 
the opportunity for reassortment (24). This growth advan-
tage over seasonal viruses was in agreement with the fact 
that selected viruses mostly contained pandemic (H1N1) 
2009 genes. The use of reverse genetics enables production 
of all gene segments at approximately similar copy num-
bers on transfection, whereas after double infection with 2 
viruses, in vitro or in ovo viruses may differ in replication 
capacity, resulting in a bias of reassortants produced.
Notably, the polymerase gene segments of seasonal 
infl uenza A (H1N1) and seasonal infl uenza A (H3N2) vi-
ruses frequently substituted for the polymerase genes of 
the pandemic (H1N1) 2009 virus in vitro. In minigenome 
assays, the polymerase complex activity of the wild-type 
pandemic (H1N1) 2009 virus was relatively low, and re-
placement of various polymerase genes of the pandem-
ic (H1N1) 2009 virus increased this activity. However, 
polymerase complexes with the highest activity in mini-
genome assays were not necessarily the ones detected in 
the reassortant viruses (data not shown). This apparent 
discrepancy is probably a result of the different param-
eters under investigation in the 2 assays, in particular, the 
production of mRNA vs. all viral RNAs.
Virus titers for pandemic (H1N1) 2009–seasonal in-
fl uenza A (H1N1) PB2PA and pandemic (H1N1) 2009–
seasonal infl uenza A (H1N1) PB2 in the lungs and trachea 
of ferrets were lower than titers in ferrets inoculated with 
wild-type pandemic (H1N1) 2009 virus, suggesting that 
both pandemic (H1N1) 2009–seasonal infl uenza A (H1N1) 
reassortant viruses were attenuated in ferrets, at least for 
replication in the lower respiratory tract. The reassortants 
between pandemic (H1N1) 2009 and seasonal infl uenza 
A (H3N2) viruses replicated at slightly higher rates than 
wild-type pandemic (H1N1) 2009 virus in vitro. Moreover, 
virus shedding of pandemic (H1N1) 2009–seasonal infl u-
enza virus A (H3N2) NA from the nose, lungs, and trachea 
of inoculated ferrets was slightly higher than wild-type 
pandemic (H1N1) 2009 virus. Although the differences in 
replication and shedding were small and not statistically 
signifi cant because of the small numbers of animals in each 
group, the pandemic (H1N1) 2009–seasonal infl uenza A 
(H3N2) viruses were not attenuated in ferrets.
Inoculation of the reassortant pandemic (H1N1)–sea-
sonal infl uenza A (H3N2) NA (either with or without the 
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Table 2. Virus antigen expression and severity of lesion in different tissues of the lung of 3 ferrets inoculated with pandemic (H1N1) 
2009 or reassortant pandemic (H1N1) 2009 viruses* 
Virus
Cumulative score per tissue 
Bronchial surface 
epithelium
Bronchial submucosal 
epithelium
Bronchiolar
epithelium
Alveolar
epithelium
IHC H&E IHC H&E IHC H&E IHC H&E
Pandemic (H1N1) 2009 0, 0, 0† 0, 0, 0 0, 0, 1 0, 0, 1 0, 0, 1 0, 0, 1 0, 0, 0 0, 0, 0 
Pandemic (H1N1) 2009–seasonal 
influenza A (H1N1) PB2PA 
0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 
Pandemic (H1N1) 2009–seasonal 
influenza A (H1N1) PB2 
0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 
Pandemic (H1N1) 2009–seasonal 
influenza A (H3N2) PB1NA 
1, 1, 0 0, 1, 0 2, 1, 0 1, 1, 0 2, 1, 0 1, 1, 0 1, 1, 0 1, 1, 1 
Pandemic (H1N1) 2009–seasonal 
influenza A (H3N2) NA 
1, 1, 1 0, 1, 1 1, 0, 3 1, 0, 3 2, 2, 3 2, 2, 3 1, 0, 1 1, 1, 1 
*IHC, immunohistochemistry to detected virus antigen expression; H&E, hematoxylin and eosin staining to analyze severity of inflammation; PB, basic 
polymerase; PA, acidic polymerase; NA, neuraminidase.  
†Individual scores (as indicated in the Methods section) for 3 ferrets are listed. 
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PB1 of seasonal infl uenza virus A [H3N2]) resulted in 
higher expression of virus antigen and more severe lesions 
at all levels of the lower respiratory tract compared with in-
oculation of wild-type pandemic (H1N1) 2009 virus (Table 
2; Figure 4). In a previous study, the wild-type pandemic 
(H1N1) 2009 virus was detected more abundantly in the 
lower airways of ferrets than in the present study (18). We 
attribute this difference to the use of a virus isolate rather 
than a virus generated by reverse genetics and to a differ-
ent batch of ferrets in the previous study. In the present 
study, all viruses were produced with reverse genetics and 
can thus be compared directly. Moreover, the reassortant 
pandemic (H1N1) 2009 virus with the NA of the seasonal 
infl uenza virus A (H3N2) was more pathogenic than both 
sources of pandemic (H1N1) 2009 virus, either the wild-
type isolate or the virus derived by reverse genetics. In-
creased severity of lesions may be related to higher virus 
replication in the lung, to stronger host immune responses, 
or both (25). 
We conclude that the pandemic (H1N1) 2009 virus 
has the potential to reassort with seasonal infl uenza virus 
A (H1N1) and infl uenza virus A (H3N2) and that such re-
assortment events could result in viruses with increased 
pathogenicity in ferrets. Although increased pathogenic-
ity in ferrets cannot be extrapolated directly to increased 
pathogenicity in humans, ferrets are susceptible to natural 
infection and respiratory disease and lung pathology devel-
op in a manner similar to the that in humans infected with 
seasonal, avian, or pandemic infl uenza viruses. Thus, the 
ferret model is generally thought to be a good animal model 
for infl uenza in humans (26,27). Patterns of infl uenza virus 
attachment to cells of the respiratory tract are also similar 
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Figure 4. Examples of virus antigen expression and severity of lesions in different tissues of the lungs of ferrets. A) Bronchial surface; 
B) bronchial submucosal gland; C) bronchiole; D) alveolus. Two of 3 ferrets inoculated with wild-type pandemic (H1N1) 2009 virus had 
neither virus antigen expression (fi rst column) nor associated lesions (second column) in the lung at day 3 postinoculation. In contrast, all 
3 ferrets inoculated with reassortant pandemic (H1N1) 2009–seasonal infl uenza (H3N2) virus neuraminidase had virus antigen expression 
in bronchi, bronchial submucosal glands, bronchioles, and alveoli (third column), associated with epithelial degeneration and necrosis 
and infi ltration of infl ammatory cells, predominantly neutrophils (fourth column). IHC, immunohistochemistry; H&E, hematoxylin and eosin 
stain. Original magnifi cation ×400.
Pandemic (H1N1) 2009 Virus Reassortment
in ferrets and humans (28), and the ferret model has further 
been used successfully for studies on virus transmission 
through respiratory droplets or aerosols (18,29).
All reassortants were transmitted between ferrets 
through aerosol or respiratory droplets. These results dem-
onstrate that some reassortants between pandemic (H1N1) 
2009 and seasonal infl uenza A (H3N2) were viable, re-
mained transmissible, and were more pathogenic than the 
wild-type pandemic (H1N1) 2009 virus and emphasize the 
importance of monitoring reassortant viruses in surveil-
lance programs because reassortment events may affect 
pathogenicity.
Although viruses with the NA gene (with or without 
the PB1 gene) of seasonal infl uenza A (H3N2) were iden-
tifi ed here as potentially fi t virus reassortants, reassortant 
viruses with other gene constellations may have selective 
advantages in humans as well. The 1968 infl uenza virus A 
(H3N2) pandemic also continued to reassort after the pan-
demic year, resulting in viruses during 1969–1971 with a 
different N2 gene than those earlier in the pandemic (30). 
Reassortants of infl uenza virus A (H1N2) with the HA 
of seasonal infl uenza A (H1N1) and the NA of seasonal 
infl uenza A (H3N2) viruses have been isolated from hu-
mans during previous infl uenza seasons, thereby confi rm-
ing that reassortant infl uenza viruses with such an HA/NA 
combination can emerge in humans (15,16). Moreover, in-
fl uenza (H1N2) viruses frequently have been detected in 
pigs around the world (31). Therefore, we recommend that 
reassortant of pandemic (H1N1) 2009 infl uenza viruses be 
monitored closely in surveillance programs, particularly 
when changes in pathogenicity or transmission in humans 
become apparent. 
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